Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390975 · ClinicalTrials.gov registry record · Phase 4
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
A Phase 4 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00390975 is a Phase 4 study that was terminated before completion, run by Novartis. The registered enrollment target is 40 participants.
The verdict
NCT00390975, a Phase 4 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390975
The ClinicalTrials.gov registry entry for NCT00390975 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00390975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390975 about?
NCT00390975 is a clinical study titled "Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis". This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.
What is the current status of trial NCT00390975?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2007-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00390975?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00390975?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.